Anxo Pharmaceutical Co., Ltd. (6677.TWO)
TWD 24.2
(-0.21%)
TWD 24.2
(-0.21%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -2.65 Million | 71.26 Million | 78.35 Million | 59.87 Million | 64.47 Million |
| Net Income | 38.68 Million | -4.71 Million | 24.32 Million | 48.91 Million | 24.11 Million |
| Depreciation & Amortization | 74.55 Million | 74.21 Million | 74.37 Million | 81 Million | 80.92 Million |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | 5.31 Million | 4.73 Million | 747 Thousand | - | 159 Thousand |
| Change in working capital | -108.07 Million | 7.09 Million | -21.44 Million | -67.45 Million | -12.27 Million |
| Other non-cash items | 14.18 Million | 13.54 Million | 11.64 Million | 13.47 Million | -28.44 Million |
| Investing Cash Flow | -179.24 Million | -22.41 Million | -37.36 Million | -11.88 Million | -38.16 Million |
| Investments in PPE | -58.04 Million | -16.62 Million | -33.9 Million | -15.97 Million | -23.08 Million |
| Acquisitions | 3.35 Million | - | - | - | - |
| Investment purchases | -125.03 Million | -5.16 Million | - | - | -9.21 Million |
| Sales/Maturities of investments | - | - | 236 Thousand | 2.73 Million | -9.21 Million |
| Other Investing Activities | 476 Thousand | -1.09 Million | 85 Thousand | 21 Thousand | -15.07 Million |
| Financing Cash Flow | 236 Million | -21.71 Million | -34.57 Million | -17.85 Million | -2.57 Million |
| Debt repayment | -87.81 Million | -10.28 Million | -26.39 Million | -93.1 Million | -48.01 Million |
| Dividends payments | - | - | - | -11.46 Million | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | 337.5 Million | - | - | 95.52 Million | - |
| Other Financing Activities | 296.11 Million | -600 Thousand | 678 Thousand | 1.15 Million | -50 Million |
| Accounts receivables | -9.01 Million | -32.47 Million | -13.38 Million | -9.75 Million | -31.23 Million |
| Accounts payables | -19.83 Million | - | - | - | - |
| Inventory | -40.76 Million | -4.21 Million | 28.14 Million | -56.49 Million | 27.97 Million |
| Other working capital | -31.09 Million | 10.35 Million | -39 Million | 38 Million | -9.01 Million |
| Cash at beginning of period | 241.32 Million | 214.18 Million | 207.76 Million | 177.63 Million | 153.89 Million |
| Cash at end of period | 295.43 Million | 241.32 Million | 214.18 Million | 207.76 Million | 177.63 Million |
| Capital Expenditure | -58.04 Million | -16.62 Million | -33.9 Million | -15.97 Million | -23.08 Million |
| Effect of forex changes on cash | - | - | - | - | - |
| Net cash flow / Change in cash | 54.11 Million | 27.13 Million | 6.42 Million | 30.13 Million | 23.74 Million |
| Free Cash Flow | -60.69 Million | 54.64 Million | 44.45 Million | 43.9 Million | 41.38 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -17.56 Million | -17.56 Million | 38.68 Million | 7.67 Million | 7.67 Million | 3.25 Million |
| Depreciation & Amortization | 18.93 Million | 18.93 Million | 74.55 Million | 17.91 Million | 17.91 Million | 18.86 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 1.23 Million | - | 5.31 Million | 1.5 Million | 1.5 Million | 1.15 Million |
| Change in working capital | -9.38 Million | -9.38 Million | -108.07 Million | -20.29 Million | -20.29 Million | -20.13 Million |
| Other non-cash items | 23.44 Million | 24.68 Million | 14.18 Million | -4.6 Million | -4.6 Million | -6.65 Million |
| Investing Cash Flow | 17.49 Million | 17.49 Million | -179.24 Million | -75.54 Million | -75.54 Million | -14.07 Million |
| Investments in PPE | -7.87 Million | -7.87 Million | -58.04 Million | -15.48 Million | -15.48 Million | -13.43 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | -125.03 Million | - | - | - |
| Sales/Maturities of investments | 56.18 Million | - | - | - | - | - |
| Other Investing Activities | 25.36 Million | 25.36 Million | 476 Thousand | -60.06 Million | -60.06 Million | -646.5 Thousand |
| Financing Cash Flow | -28.08 Million | -28.08 Million | 236 Million | 122.46 Million | 122.46 Million | -4.45 Million |
| Debt repayment | -48.76 Million | - | -87.81 Million | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | 337.5 Million | - | - | - |
| Other Financing Activities | -28.08 Million | -28.08 Million | 296.11 Million | 122.46 Million | 122.46 Million | -4.45 Million |
| Accounts receivables | -6.51 Million | -6.51 Million | -9.01 Million | -15.94 Million | -15.94 Million | 11.44 Million |
| Accounts payables | 33.54 Million | - | - | - | - | - |
| Inventory | -3 Million | -3 Million | -40.76 Million | -10.7 Million | -10.7 Million | -9.67 Million |
| Other working capital | 131 Thousand | 131 Thousand | -31.09 Million | 6.35 Million | 6.35 Million | -21.9 Million |
| Cash at beginning of period | 309.97 Million | - | 241.32 Million | - | - | - |
| Cash at end of period | 6.07 Million | 6.07 Million | 295.43 Million | 49.11 Million | 49.11 Million | -22.05 Million |
| Capital Expenditure | -7.87 Million | -7.87 Million | -58.04 Million | -15.48 Million | -15.48 Million | -13.43 Million |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -303.9 Million | 6.07 Million | 54.11 Million | 49.11 Million | 49.11 Million | -22.05 Million |
| Free Cash Flow | 8.79 Million | 8.79 Million | -60.69 Million | -13.29 Million | -13.29 Million | -16.95 Million |
0JW2
MEOH
BL
CLBTW
AKSI
5871